Pulmonx share price logo

Pulmonx

NASDAQ: LUNG

$2.58

-0.25

(-8.66%)

as on

Pulmonx Stock Performance

as on November 6, 2026 at 7:59 am IST

  • Day's Low

    Day's High

    $2.49
    $2.90
    downward going graph

    3.49%

    Downside

    12.40%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.13
    $3.25
    downward going graph

    56.20%

    Downside

    25.97%

    Upside

    downward going graph

Pulmonx share price movements today

Previous Close
$2.83
Open
$2.90
Volume
651.7K
Market Cap
$116.8M
Day's Low - High
$2.49 - $2.90
52 Week Low - High
$1.13 - $3.25

Pulmonx Historical Returns

1 Month Return
+ 50.53 %
3 Month Return
+ 42.93 %
1 Year Return
+ 66.47 %
3 Year Return
-71.47 %
5 Year Return
-93.73 %

Pulmonx Stock Fundamentals & Key Indicators

Check Pulmonx market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$116.8M

EPS (TTM)

-1

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-2.72

Industry PE ratio

-3.70

PEG Ratio

-0.08

EBITDA

-36.8M

Revenue (TTM)

88.8M

Profit Margin

77.42%

Return On Equity TTM

-98.23%

Pulmonx vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Pulmonx with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Pulmonx image
Pulmonx
Buy$116.8M-93.73%-2.7277.42%0.00%
Edwards Lifesciences image
Edwards Lifesciences
StrongBuy$54.9B-16.25%54.7177.98%0.00%
Medtronic image
Medtronic
Buy$127.0B-14.65%24.1866.69%2.89%
Stryker image
Stryker
StrongBuy$116.8B22.99%32.8665.52%1.13%
Abbott Laboratories image
Abbott Laboratories
StrongBuy$183.8B-16.84%39.3357.12%2.37%
See all

Stock Returns calculator for Pulmonx Stock including INR - Dollar returns

The Pulmonx stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Pulmonx investment value today

Current value as on today

₹1,61,907

Returns

₹61,907

(+61.91%)

Returns from Pulmonx Stock

₹51,765 (+51.76%)

Dollar Impact

₹10,142 (+10.14%)

Analyst Recommendation on Pulmonx Stock

Based on 1 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 1 analysts, 100% of analysts recommend a 'BUY' rating for Pulmonx. Average target price of $3.7

Pulmonx Share Price Target

Get share price movements and forecasts by analysts on Pulmonx.

What analysts predicted

30.27%UPSIDE

Target Price

$3.7

Current Price

$2.58

Analyzed by

1 Analysts

High

$5

Target

$3.70

Low

$5

Pulmonx target price $3.7, a slight upside of 30.27% compared to current price of $2.58. According to 1 analysts rating.

Indian Investors' Interest in Pulmonx Stock

Search interest for Pulmonx Stock has increased by 756% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:756% versus previous 30 day period

Pulmonx Quarterly Profit & Loss

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Revenue
20
20
23
22
23
21
22
20
22
22
Gross Profit
15
15
17
16
17
16
17
16
17
17
Operating Income
-15
-14
-13
-14
-14
-14
-9
-12
-9
-7
EBITDA
-13
-12
-12
-14
-13
-12
-9
-12
-8
-6
Interest Expense
0
0
0
0
0
0
0
0
1
1
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-15
-13
-13
-14
-14
-13
-10
-13
-9
-8
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-15
-14
-13
-14
-15
-13
-10
-13
-10
-8
Net Profit Margin
73.65%
73.70%
74.02%
72.51%
72.11%
74.65%
77.62%
77.94%
77.97%
76.19%

Pulmonx Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
20
32
32
48
53
68
83
90
Gross Profit
12
22
21
35
39
50
62
67
Operating Income
-15
-17
-32
-47
-58
-61
-57
-53
EBITDA
-15
-17
-28
-46
-55
-55
-50
-49
Interest Expense
2
2
3
0
1
3
3
3
Depreciation
0
0
0
0
1
1
1
1
Income Before Tax
-18
-20
-32
-48
-58
-60
-55
-53
Income Tax Expense
0
0
0
0
0
0
0
0
Net Income
-18
-20
-32
-48
-58
-60
-56
-54
Net Profit Margin
61.42%
68.77%
64.77%
73.59%
74.29%
73.90%
74.00%
74.19%

Pulmonx Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Net Income
-15
-14
-13
-14
-15
-13
-10
-13
-10
-8
Operating Cash Flow
-5
-7
-6
-13
-3
-8
-7
-10
-5
-3
Investing Cash Flow
0
6
14
16
5
8
0
0
0
0
Financing Cash Flow
0
0
0
0
0
0
0
2
0
0
Change in Cash
-6
0
7
3
0
1
-6
-8
-5
-3

Pulmonx Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-18
-20
-32
-48
-58
-60
-56
-54
Operating Cash Flow
-18
-20
-30
-41
-45
-37
-31
-32
Investing Cash Flow
0
-14
12
-46
-4
-2
17
30
Financing Cash Flow
12
45
234
4
2
21
1
0
Change in Cash
-5
10
217
-83
-46
-18
-12
-1

Global Institutional Holdings in Pulmonx

Check out the Institutions with significant holdings in Pulmonx.

Funds
Holdings
Theofanis Kolokotrones
10.74%
PRIMECAP Odyssey Funds
8.15%
Glendon E. III French
4.79%
Vanguard
3.85%
VANGUARD INDEX FUNDS
3.70%
See all

Pulmonx News & Key Events

  • img

    Today's Timeline - 27 October

    Wed, 01:50 AM

    -

    Pulmonx reports Q3 EPS of 19c, revenue of $22.84M, exceeding consensus expectations.

Insights on Pulmonx

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 20.58M → 22.83M (in $), with an average increase of 4.9% per quarter

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, LUNG has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -13.65M → -8.39M (in $), with an average increase of 27.8% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, LUNG stock has moved up by 59.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Edwards Lifesciences Corp has given 48.1% return, outperforming this stock by 118.7%

About Pulmonx

Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
OrganisationPulmonx
Headquarters700 Chesapeake Drive, Redwood City, CA, 94063, US
IndustryMedical - Devices
CEOGlendon E. French

Key Management of Pulmonx

Name

Title

Mr. Jérôme Erath

Senior VP & GM of International

Dr. Narinder S. Shargill Ph.D.

Senior Vice President of Global Medical & Clinical Affairs

Mr. John B. McKune

VP of Finance & Corporate Controller

Mr. Glendon E. French

CEO, President & Director

Dr. Derrick Sung Ph.D.

CFO & COO

Mr. David A. Lehman J.D.

General Counsel & Secretary

Mr. Srikanth Radhakrishnan

Chief Science & Technology Officer

Ms. Marcee M. Maroney

Vice President of Marketing

Mr. Geoffrey Beran Rose

Chief Commercial Officer

FAQs

What is Pulmonx share price today?

Pulmonx share price today is $2.58 as on at the close of the market. Pulmonx share today touched a day high of $2.90 and a low of $2.49.

What is the 52 week high and 52 week low for Pulmonx share?

Pulmonx share touched a 52 week high of $3.25 on and a 52 week low of $1.13 on . Pulmonx stock price today i.e. is closed at $2.58,which is 20.62% down from its 52 week high and 128.32% up from its 52 week low.

What is Pulmonx's market capitalisation today?

Pulmonx market capitalisation is $0.00T as on .

How to invest in Pulmonx Stock (LUNG) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Pulmonx on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Pulmonx Stock (LUNG) from India?

Indian investors can start investing in Pulmonx (LUNG) shares with as little as ₹94.4749984741211 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹944.75 in Pulmonx stock (as per the Rupee-Dollar exchange rate as on ). Based on Pulmonx share’s latest price of $2.58 as on November 6, 2026 at 2:29 am IST, you will get 3.8760 shares of Pulmonx. Learn more about fractional shares .

What are the returns that Pulmonx has given to Indian investors in the last 5 years?

Pulmonx stock has given -93.73% share price returns and 27.92% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?